[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

CA Tumor Markers Testing Market 2021: US, Europe, Japan--Emerging Opportunities, Supplier Shares and Strategies, Volume and Sales Segment Forecasts, Emerging Technologies and Opportunities

July 2017 | 278 pages | ID: CAFBCAACCEDEN
Venture Planning Group

US$ 5,450.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the worldwide cancer testing market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion worldwide. This report presents a detailed analysis of the CA 15-3/27.29, CA 19-9, and CA 125 testing market in the US, Europe (France, Germany, Italy, Spain, UK) and Japan, including clinical significance and current laboratory practice; 5-year test volume and sales forecasts by country and market segment; as well as sales and market shares for major suppliers. The report also examines market applications of DNA probes, biochips/microarrays, monoclonal antibodies, immunoassays, IT, chromosome analysis, and other technologies; reviews features and operating characteristics of automated analyzers; profiles leading suppliers and recent market entrants developing innovative technologies and products; and identifies alternative market penetration strategies and entry barriers/risks.

Contains 278 pages and 40 tables
I. INTRODUCTION

II. CA TUMOR MARKERS WORLDWIDE MARKET AND TECHNOLOGY OVERVIEW

A. CA Tumor Markers: Clinical Significance and Laboratory Practices
  1. CA 15-3/27.29
  2. CA 19-9
  3. CA 125
B. Instrumentation Review And Market Needs
  1. Abbott AxSYM
  2. Abbott Architect c4000
  3. Abbott Architect i200  Series
  4. Abbott Architect ci820  System
  5. Beckman Coulter UniCel Series
  6. Beckman Coulter Access
  7. Binding Site ESP600
  8. bioMerieux Mini Vidas
  9. Carolina Chemistries BioLis 24i
  10. DiaSorin Liaison
  11. Horiba ABX Pentra 400
  12. Inverness DS2
  13. J&J Vitros ECi/ECiQ
  14. J&J Vitros 3600
  15. J&J Vitros 5600
  16. Olympus AU5400
  17. Olympus AU3000i
  18. Olympus AU2700
  19. Roche Modular Analytics
  20. Roche Cobas Integra 400
  21. Roche Cobas Integra 40  Plus
  22. Roche Elecsys
  23. Roche Cobas c311
  24. Siemens ADVIA Centaur
  25. Siemens Dimension
  26. Siemens Dimension RxL Max
  27. Siemens Dimension Vista 500
  28. Siemens Immulite
  29. Siemens Stratus
  30. Tosoh AIA-Series
  31. Vital Diagnostics ATAC 8000
  32. Vital Diagnostics Envoy 500
C. Current and Emerging Technologies
  1. Monoclonal and Polyclonal Antibodies
  2. Immunoassays
    a. Technological Principle
    b. Radioimmunoassay (RIA)
    c. Enzyme Immunoassays (EIA)
      Overview
      ELISA
      Immunofiltration
      Particle-Membrane Capture Immunoassay
      Enzyme Amplification
    d. Fluorescent Immunoassays
    e. Luminescence
      Chemiluminescence
      Bioluminescence
    f. Latex Agglutination
    g. Immunoprecipitation
    h. Affinity Chromatographu
    i. Liposome Flow-Injection Immunoassay
  3. Molecular Diagnostics
    a. Technology Overview
    b. Amplification Methods
      PCR
      DAP-PCR
      Immuno-PCR
      QC-PCR
      CAR
      DNA
      HPA
      LCR
      NASBA
      QBR
      SDA
      3 SR, and others
  4. Chromosome Analysis
    a. Chronic Myelogenous Leukemia (CML)
    b. Acute Myeloid Leukemia (AML)
    c. Acute Lymphoblastic Leukemia (ALL)
    d. Malignant Lymphomas
      Lymphoid Malignancies
    e. Chronic Lymphocytic Leukemia (CLL)
    f. Solid Cancers
    g. Chromosomal Translocation and Oncogenes
  5. Artificial Intelligence
  6. Flow Cytometry
  7. Two Dimensional Gel Electrophoresis (2-DGE)
  8. Biosensors
  9. Competing/Complementing Technologies
    a. CT
    b. MRI
    c. NMR
    d. PET
    e. Photonics Spectroscopy
D. Personal Testing

III. FRANCE: MARKET SIZE, GROWTH AND MAJOR SUPPLIERS’ SALES AND MARKET SHARES

IV. GERMANY: MARKET SIZE, GROWTH AND MAJOR SUPPLIERS’ SALES AND MARKET SHARES

V. ITALY: TEST VOLUME AND DIAGNOSTICS SALES FORECAST BY MARKET SEGMENT

VI. JAPAN: MARKET SIZE, GROWTH AND MAJOR SUPPLIERS’ SALES AND MARKET SHARES

VII. SPAIN: MARKET SIZE, GROWTH AND MAJOR SUPPLIERS’ SALES AND MARKET SHARES

VIII. U.K.: TEST VOLUME AND DIAGNOSTICS SALES FORECAST BY MARKET SEGMENT

IX. U.S.A.: MARKET SIZE, GROWTH AND MAJOR SUPPLIERS’ SALES AND MARKET SHARES

X. DESIGN CRITERIA FOR DECENTRALIZED TESTING PRODUCTS

XI. ALTERNATIVE MARKET PENETRATION STRATEGIES

A. Internal Development
B. Collaborative Arrangements
C. University Contracts
D. Distribution Strategies
  1. Marketing Approaches
  2. Product Complexity
  3. Customer Preference
  4. Established Suppliers
  5. Emerging Suppliers
  6. Major Types of Distributors
  7. Market Segmentation Factor

XII. POTENTIAL MARKET ENTRY BARRIERS AND RISKS

A. Market Maturity
B. Cost Containment
C. Competition
D. Technological Edge and Limitations
E. Patent Protection
F. Regulatory Constraints
G. Decentralized Testing Market Challenges

XIII. @COMPETITIVE PROFILES

Abbott
AdnaGen
Applied Gene Technologies
Arca
Beckman Coulter/Danaher
Becton Dickinson
Biomedical Diagnostics
bioMerieux
Bio-Rad
Cepheid
Correlogic Systems
Dako
Decode
Diadexus
Diagnocure
Diasorin
Eiken Chemical
Enterix
Enzo Biochem
Epigenomics
Exact Sciences
Fujirebio
Gen-Probe
Guided Therapeutics
Hologic
Ipsogen
Kreatech
Kyowa Medex
Life Technologies
Mackay Life Sciences
Myriad Genetics
Nanogen Elitech
OncoLab
Ortho-Clinical Diagnostics
Panacea Pharmaceuticals
Polartechnics
Polymedco
PreMD
Qiagen
Radient Pharmaceuticals
Roche
Scienion
Sequenom
Siemens Healthcare
Takara Bio
Targeted Diagnostics & Therapeutics
Tosoh
Veridex
Wako Pure Chemicals
Wallac/PE
Zila
CA TUMOR MARKERS: US, EUROPE, JAPAN
Test Volume, Sales Forecasts and Supplier Shares by Country

LIST OF TABLES

Major Companies Developing or Marketing CA 15-3/27.29 Tests
Major Companies Developing or Marketing CA 19-9 Tests
Major Companies Developing or Marketing CA 125 Tests
France CA 15-3/27.29 Test Volume and Diagnostics Sales by Market Segment
France CA 19-9 Test Volume and Diagnostics Sales by Market Segment
France CA 125 Test Volume and Diagnostics Sales by Market Segment
France CA 15-3/27.29 Testing Market by Major Supplier
France CA 19-9 Testing Market by Major Supplier
France CA 125 Testing Market by Major Supplier
Germany CA 15-3/27.29 Test Volume and Diagnostics Sales by Market Segment
Germany CA 19-9 Test Volume and Diagnostics Sales by Market Segment
Germany CA 125 Test Volume and Diagnostics Sales by Market Segment
Germany CA 15-3/27.29 Testing Market by Major Supplier
Germany CA 19-9 Testing Market by Major Supplier
Germany CA 125 Testing Market by Major Supplier
Italy CA 15-3/27.29 Test Volume and Diagnostics Sales by Market Segment
Italy CA 19-9 Test Volume and Diagnostics Sales by Market Segment
Italy CA 125 Test Volume and Diagnostics Sales by Market Segment
Japan CA 15-3/27.29 Test Volume and Diagnostics Sales by Market Segment
Japan CA 19-9 Test Volume and Diagnostics Sales by Market Segment
Japan CA 125 Test Volume and Diagnostics Sales by Market Segment
Japan CA 15-3/27.29 Testing Market by Major Supplier
Japan CA 19-9 Testing Market by Major Supplier
Japan CA 125 Testing Market by Major Supplier
Spain CA 15-3/27.29 Test Volume and Diagnostics Sales by Market Segment
Spain CA 19-9 Test Volume and Diagnostics Sales by Market Segment
Spain CA 125 Test Volume and Diagnostics Sales by Market Segment
Spain CA 15-3/27.29 Testing Market by Major Supplier
Spain CA 19-9 Testing Market by Major Supplier
Spain CA 125 Testing Market by Major Supplier
U.K. CA 15-3/27.29 Test Volume and Diagnostics Sales by Market Segment
U.K. CA 19-9 Test Volume and Diagnostics Sales by Market Segment
U.K. CA 125 Test Volume and Diagnostics Sales by Market Segment
U.S.A. CA 15-3/27.29 Test Volume and Diagnostics Sales by Market Segment
U.S.A. CA 19-9 Test Volume and Diagnostics Sales by Market Segment
U.S.A. CA 125 Test Volume and Diagnostics Sales by Market Segment
U.S.A. CA 15-3/27.29 Testing Market by Major Supplier
U.S.A. CA 19-9 Testing Market by Major Supplier
U.S.A. CA 125 Testing Market by Major Supplier


More Publications